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Cell fate decisions during haematopoiesis are governed
by lineage-speciﬁc transcription factors, such as RUNX1,
SCL/TAL1, FLI1 and C/EBP family members. To gain
insight into how these transcription factors regulate
the activation of haematopoietic genes during embryonic
development, we measured the genome-wide dynamics
of transcription factor assembly on their target genes
during the RUNX1-dependent transition from haemogenic
endothelium (HE) to haematopoietic progenitors. Using a
Runx1 /  embryonic stem cell differentiation model
expressing an inducible Runx1 gene, we show that in the
absence of RUNX1, haematopoietic genes bind SCL/TAL1,
FLI1 and C/EBPband that this early priming is required for
correct temporal expression of the myeloid master regu-
lator PU.1 and its downstream targets. After induction,
RUNX1 binds to numerous de novo sites, initiating a local
increase in histone acetylation and rapid global alterations
in the binding patterns of SCL/TAL1 and FLI1. The acqui-
sition of haematopoietic fate controlled by Runx1 therefore
does not represent the establishment of a new regulatory
layer on top of a pre-existing HE program but instead
entails global reorganization of lineage-speciﬁc transcrip-
tion factor assemblies.
The EMBO Journal (2012) 31, 4318–4333. doi:10.1038/
emboj.2012.275; Published online 12 October 2012
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Keywords: cell fate decisions; endothelial–haematopoietic
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Introduction
During embryogenesis blood cells arise from the mesoderm
via haemangioblast cells, a cell type capable of generating
both endothelial and haematopoietic cells (Kennedy et al,
1997; Choi et al, 1998; Huber et al, 2004). These cells
differentiate into the haemogenic endothelium (HE) which
then undergoes a transition from an adherent, epithelial-like
cell into a non-adherent blood cell precursor, a process called
the endothelial–haematopoietic transition (Chen et al, 2009;
Eilken et al, 2009; Lancrin et al, 2009; Kissa and Herbomel,
2010). Each of these differentiation steps is controlled by
sequence-speciﬁc DNA-binding proteins. Mice lacking the
ETS-factor family member FLI1 die from defects in blood
vessel formation and show multiple haematopoietic defects
(Spyropoulos et al, 2000), indicating that this factor is
involved in the regulation of endothelial and haemato-
poietic gene expression programs. Mice with a deletion of
the Tal1 gene that encodes the transcription factor SCL/TAL1
fail to generate any haematopoietic precursors and develop
vascular defects (Robb et al, 1995; Porcher et al, 1996;
Visvader et al, 1998). Using mouse embryonic stem (ES)
cell differentiation as a model, it was later shown that SCL/
TAL1 is required to form the HE (D’Souza et al, 2005; Lancrin
et al, 2009). The same study together with experiments using
conditional knockout mice demonstrated that the actual
endothelial–haematopoietic transition is dependent on the
presence of the transcription factor RUNX1 (Chen et al, 2009,
2011; Eilken et al, 2009; Lancrin et al, 2009). The develop-
ment of mature blood cells from haematopoietic precursors
requires additional transcription factors and includes the
ETS-family member PU.1 whose balanced expression is
required for correct myeloid and lymphoid development
(McKercher et al, 1996; Scott et al, 1997; Rosenbauer et al,
2006; Leddin et al, 2011). Last, but not least, C/EBP family
members are critical for myelopoiesis. C/EBPa regulates the
formation of granulocyte-macrophage precursor cells and
fulﬁlls important roles in haematopoietic stem cell (HSC)
maintenance (Zhang et al, 2004; Bereshchenko et al, 2009)
and C/EBPb is involved in the control of macrophage
function (Tanaka et al, 1995). Mice lacking both factors die
early in embryogenesis (Begay et al, 2004).
Transcription factors determine cell fate decisions by con-
trolling the correct temporal sequence of lineage-speciﬁc
gene activation or repression. This notion was emphasized
by experiments in Drosophila that combined the determi-
nation of global binding patterns of transcription factors
throughout a developmental pathway with mathematical
modelling. This demonstrated that such knowledge is sufﬁ-
cient to predict the developmental activity of cis-regulatory
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phenotypic and developmental consequences of the removal
of each of the described transcription factors are well
described, little is known of what drives their dynamic
and speciﬁc assembly on their target genes during the
process of haematopoietic speciﬁcation. Recent genome-
wide analyses of transcription factor binding have given
insights into the complexities of combinations of trans-
cription factors targeting lineage-speciﬁc genes (Wilson
et al, 2010). However, other studies revealed that the same
transcription factors are able to interact with different
partners in different cell types and display different binding
patterns (Pencovich et al, 2010; Hannah et al,2 0 1 1 ;
Trompouki et al, 2011). Little is known about whether
similar transitions govern the onset of haematopoiesis and
how differential transcription factor assembly relates to cell
fate decisions.
Here, we addressed these questions by employing a
well-established in vitro model of haematopoiesis, the
differentiation of ES cells into haematopoietic precursor
cells (Choi et al, 1998; Sroczynska et al, 2009b). This
system provides a traceable model to gain mechanistic
insights into mechanistic the regulation of early events in
embryonic haematopoiesis that are difﬁcult to study in
the mouse. Using an ES cell line that expresses an inducible
form of RUNX1 in a Runx1 /  genetic background
(Lancrin et al, 2009) we measured the dynamic assembly of
speciﬁc transcription factor complexes containing C/EBPb,
SCL/TAL1 and FLI1 during the RUNX1-dependent endothelial-
to-haematopoietic transition, both at the genome-wide and
at the gene-speciﬁc level. We ﬁnd that in the absence of
RUNX1 in the HE C/EBPb, SCL/TAL1 and FLI1 bind to
speciﬁc cis-regulatory elements of haematopoiesis-speciﬁc
genes and genes involved in changing cell shape. RUNX1
binds to the same genes and its induction leads to a rapid
shift in the binding of SCL/TAL1 and FLI1, which is complete
in multipotent precursor cells. Our data are consistent with
a model by which the expression of RUNX1 in the HE
orchestrates the assembly of a haematopoiesis-speciﬁc
global pattern of transcription factor binding.
Results
Coordinated and hierarchical expression of
haematopoietic regulator genes during ES cell
differentiation
We ﬁrst measured the accurate levels and the kinetics of
expression of genes encoding transcription factors important
for early haematopoiesis in puriﬁed cells. We differentiated
ES cells and sampled developing cells at different time points
by purifying them according to their surface marker proﬁle
using ﬂuorescence activated cell sorting (FACS) as outlined
in Figure 1A and Supplementary Figure 1A. We used an
ES cell line carrying a GFP gene in the mesoderm-speciﬁc
Brachyury locus which allowed for the puriﬁcation of
haemangioblasts by sorting cells for GFP expression and
the expression of Flk-1, a marker for endothelial cells
(Fehling et al, 2003). The next step in differentiation is the
ﬁrst stage of HE development which is deﬁned by the expres-
sion of Tie-2 and c-kit, and a low level of Runx1 mRNA. In the
second stage of HE development, Runx1 is upregulated
and CD41 appears on the surface (Lancrin et al, 2009;
Sroczynska et al, 2009a). Fully committed haematopoietic
precursor cells express high levels of c-kit and CD41. All
analysed genes showed a highly dynamic expression pattern
(Figure 1B; Supplementary Figure 1B) whereby Cebpb was
already expressed very early from the HE stage onwards
but the gene encoding the myeloid master regulator PU.1
(Pu.1/Sfpi1) was only expressed after the onset of Runx1
expression (Hoogenkamp et al, 2009). The expression of
Cebpa followed that of Pu.1. Late myeloid genes such as
the PU.1 target gene Csf1r were only detected after PU.1 was
expressed at high levels conﬁrming previous cell line studies
(Krysinska et al, 2007).
Taken together, these data show a highly dynamic expres-
sion pattern of haematopoietic regulator genes whereby
different upstream regulators independently and hierarchi-
cally feed into the expression of their downstream targets.
SCL/TAL1, FLI1 and C/EBPb associate with a large
number of genes in the HE in the absence of RUNX1
The onset of Tal1 and Fli1 expression does not depend on
RUNX1 but Runx1 is a target of FLI1 (Nottingham et al,2 0 0 7 )
and its expression follows FLI1 upregulation (Figure 1B). The
ﬁrst stage of the HE is therefore a transient cell population
and it is difﬁcult to obtain enough cells for global analyses
aimed at distinguishing the SCL/TAL1 and FLI1 regulatory
circuits from those governed by RUNX1. To gain detailed
insights into the molecular defects of haematopoiesis in the
absence of RUNX1, we used an ES cell line that expressed an
inducible form of RUNX1 in a Runx1 /  genetic back-
ground (iRUNX1) (Hoogenkamp et al, 2009; Lancrin et al,
2009). We differentiated these cells using a step-wise culture
system that allows detailed studies of the endothelial–
haematopoietic transition (outlined in Figure 2A and
Supplementary Figure 2A) and where the order of expression
of haematopoietic genes is faithfully preserved (Lancrin et al,
2009, see also Supplementary Figure 6I). Without induction,
these cells are blocked in their differentiation and accumulate
at the ﬁrst HE stage. We therefore determined the genome-
wide binding sites of SCL/TAL1 and FLI1 in the iRUNX1 cell
line in the absence of induction. We also followed up on our
ﬁnding of the very early C/EBPb expression prior to the
appearance of C/EBPa expression and determined whether
this factor was bound to its target genes at this stage. To link
transcription factor binding data with active chromatin for-
mation, we determined the binding of RNA-Polymerase II
(RNA Pol II) and measured histone H3 lysine 9 acetylation
by chromatin immunoprecipitation (ChIP) sequencing. We
found 10617 binding sites for SCL/TAL1, 8507 binding sites
for FLI1 and 10189 peaks for C/EBPb (Figure 2B;
Supplementary Table 1). Examples of binding patterns at
speciﬁc genes are shown in Figure 2C and Supplementary
Figure 2B. ChIP-sequencing data were validated by manual
analysis of different genes (Supplementary Figure 2E). We
also performed ChIPassays in cells derived from Runx1 / 
ES cells to demonstrate that factor binding was not an artifact
of leakiness of the inducible system. Also here all three
factors as well as RNA-Pol II interacted with an essential
enhancer element (30 upstream regulatory element (URE)) of
the Pu.1 (Sfpi1) locus that binds the three factors as well as
RUNX1 (Supplementary Figure 2D).
In the uninduced HE, SCL/TAL1 and FLI1 peaks showed
some overlap (Figure 2B) but very few peaks were bound by
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We subdivided these peaks according to their genomic location
(promoters, intergenic peaks and intragenic peaks) and ranked
them according to the RNA-Pol II tag count around the respec-
tive factor binding sites. We also plotted the H3K9Ac levels at
the corresponding positions (Figure 2D with manual validations
shown in Supplementary Figure 2E). This analysis showed that
binding of all factors was correlated with high levels of histone
acetylation. Only a minority of peaks for each factor resided
in promoters, while most binding sites were in intergenic
or intragenic regions. A large number of these sites were
co-occupied with RNA-Pol II and we observed a direct corre-
lation between RNA Pol II and H3K9Ac levels at these peaks.
Unbiased de novo motif discovery with peak regions for the
three factors (Figure 3A) showed that SCL/TAL1 unique
peaks were mostly associated with E-box motifs, as expected,
but also with motifs for ETS- and GATA family members, a
combination that has been associated with cis-regulatory
elements active in HSCs (Pimanda et al, 2007). C/EBPb
bound peaks associated with binding sites for inducible
factors such as AP1. This colocalization with AP1
consensus sequences was also seen with FLI1 peaks and
peaks overlapping SCL/TAL1 and FLI1. In all, 69% of all FLI1
bound peaks also contained an ETS consensus sequence
and the C/EBP consensus sequence was found in 72% of
all C/EBPb bound peaks, but only about half of the SCL/TAL1
peaks showed an E-box motif (Figure 3B).
In summary, we show (i) that SCL/TAL1, FLI1 and also
C/EBPb bind to a large number of cis-regulatory elements at
the ﬁrst stage of the HE and (ii) that many distal elements
binding these factors are also bound by RNA Polymerase II
and marked by H3K9 acetylation.
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Figure 1 Time course of expression of haematopoietic regulator genes during ES cell differentiation. (A) Schematic outline of the haemato-
poietic differentiation model. Haemangioblast (Flk1þ, Bryþ) cells are sorted from embryoid bodies on day 0 and during a 4-day blast culture
through the stage of the haemogenic endothelium give rise to haematopoietic progenitors, which can be differentiated into macrophages
(CD11bþ, F4/80þ). Relevant surface markers of sorted cell populations are indicated. (B) Relative expression analysis of haematopoietic
regulator genes in puriﬁed cells from all stages of differentiation. Flk1  cells served as control and experiments were carried out at least in
triplicates where STDEV was applied, otherwise the average of two biological duplicates and the respective values are shown.
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genes regulating haematopoiesis and cell shape
We next annotated peaks with nearby genes (Figure 3C) and
identiﬁed 2400 genes that were bound by all three factors
(Supplementary Table 3). We ﬁrst performed a gene set
enrichment analysis (GSEA) comparing the genes bound
by different combinations of the three factors with micro-
array expression data obtained from differentiating murine
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Figure 2 Genome-wide SCL/TAL1, FLI1 and C/EBPb binding in the haemogenic endothelium. (A) Schematic overview of iRUNX1 differentiation.
In RUNX1-deﬁcient iRUNX1 cells a two-step protocol was used, including a second Flk1 sort during blast culture to isolate haemogenic endothelium
cells, which are arrested at that stage. (B) Venn diagram demonstrating the intersection of SCL/TAL1, C/EBPb and FLI1 peaks. (C) UCSC genome
browser screenshots showing the binding pattern of transcription factors, RNA-Pol II and H3K9Ac at Sfpi1 (Pu.1) and Notch1 and depicting
unmanipulated aligned reads at each chromosomal location. (D) Heat maps showing the distribution of RNA-Pol II and H3K9 acetylation
around SCL/TAL1 (left), FLI1 (middle) and C/EBPb (right) binding sites within promoter/intragenic and intergenic regions. RNA Pol II and
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2007; Figure 3D; Supplementary Figure 3A). Although many
haematopoietic genes were contained in the overlap set
between FLI1 and SCL/TAL1 bound genes, the gene set
that was bound by all three factors showed the highest
enrichment score for HSC genes (Figure 3D). Genes bound
by the three factors included haematopoietic transcriptional
regulator genes such as Notch1, Pu.1, Nfe2 and Erg as well
as cytokine and cytokine receptor genes (Supplementary
Table 3). In the analysis of the physiological and system
developmental function of this gene set, haematopoiesis
featured prominently (Supplementary Figure 3B), together
with a high representation of genes involved in the regula-
tion of tissue morphology. The latter was also conﬁrmed by
a KEGG pathway analysis, which showed that genes bound
by the three factors were highly enriched in the focal adhe-
sion pathway (Supplementary Figure 3C, marked by red
asterisks). This included genes such as Flnb (Filamin B),
Fak (focal adhesion kinase), Rock2 and Bcar1, all of which
were differentially regulated after the expression of RUNX1
(Supplementary Figure 3D). This pathway is important for
the endothelial–haematopoietic transition (Yue et al, 2012),
demonstrating that besides binding to genes important
for haematopoiesis, SCL/TAL1, FLI1 and C/EBPb bind to
genes involved in regulating the morphological alterations
occurring during this process.
To examine how factor binding, RNA-Pol II occupancy,
histone acetylation and genomic location correlated with
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Figure 3 Sequence motifs and genes associated with SCL/TAL1, C/EBPb and FLI1 binding. (A) Unbiased binding motif search underlying
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uninduced HE using expression microarrays (Supplementary
Figure 3E) and plotted expression levels alongside RNA-Pol II
occupancy and H3K9Ac. This showed that the majority of the
genes were expressed irrespective of the genomic location of
the factor binding sites. We then subdivided this gene set into
a high expression set (13876 genes) and a set with low or
absent expression (8167 genes), according to absolute ex-
pression levels using a threshold value of (log2 p6). KEGG
pathway analysis of the high expression set binding all three
factors (1908 genes) demonstrated that also in this data set
the pathways involved in regulating the actin cytoskeleton
(P¼5.15 10
 8) and focal adhesion (P¼1.17 10
 9) were
highly enriched. To correlate factor binding with expression
levels, we examined the enrichment of high expression genes
in sets of genes binding each combination of one, two or all
three transcription factors. All these lists show signiﬁcant
enrichment (Supplementary Figure 3F). The set of genes
binding all three factors showed the most signiﬁcant enrich-
ment of high expression genes (1908 out of 2300,
P¼5.86 10
 77). However, within this gene set, there was
little correlation between the number of binding sites for any
of the three factors and actual gene expression levels
(Pearson coefﬁcient 0.1).
FLI1 binding at the HE stage is required for the correct
timing of Pu.1 gene expression
Our experiments demonstrate that the formation of the ﬁrst
stage of the HE is associated with a high level of SCL/TAL1
and FLI1 expression as well as low levels of RUNX1 and
C/EBPb. This is followed by the further upregulation of
RUNX1 at the second stage of the HE. The Pu.1 locus was
bound by SCL/TAL1, FLI1 and C/EBPb at the ﬁrst stage of the
HE. We showed previously that a low level of RUNX1 is
required to prime Pu.1 chromatin at the haemangioblast stage
when FLI1 expression is low/absent (Hoogenkamp et al,
2009). The elimination of the RUNX1 binding site in the
Pu.1 URE leads to an inactivation of the enhancer and a
dramatic reduction in Pu.1 mRNA levels (Huang et al, 2008).
To test whether not only RUNX1 binding, but also early
binding by FLI1 is required for the correct timing of Pu.1
expression, we generated an ES cell line where the FLI1
binding site in the URE was mutated in both alleles (Pu.1
ki/ki,
Figure 4A), but was otherwise normal. Functional effects of
this mutation on the development of myeloid cells in mice
will be described elsewhere (Staber, P, and Tenen DRG,
submitted). ES cells heterozygous for the mutated allele
(Pu.1
þ/ki) served as a control. Both cell lines were differ-
entiated and puriﬁed Flk1þ cells were subjected ﬁrst to blast
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Figure 4 The FLI1 binding site in the URE is required for the correct timing of Pu.1 upregulation. (A) Upper panel: Map of regulatory elements
of the Pu.1 gene. Transcription factor binding sites of the  14kb upstream regulatory element (URE) and promoter are highlighted in the
enlarged detailed map. DNase I hypersensitive sites are marked by vertical arrows and the transcription start site by a horizontal arrow. Lower
panel: Section of the  14kb URE containing a mutation in the FLI1 binding site. (B) Relative expression analysis during the ES cell to
macrophage differentiation in heterozygous Pu.1
þ/ki cells (control: black bars) and the homozygous Pu.1
ki/ki cells (white bars). Experiments
represent the mean values of three biological replicates.
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macrophage differentiation culture over a period of 14 days.
We measured Pu.1 expression at different time points. In
mature macrophages, Pu.1 expression levels were identical
between control and Pu.1
ki/ki cells, and precursor cell forma-
tion was unaffected (Supplementary Figure 4). However, in
Pu.1
ki/ki cells the onset of expression of Pu.1 was delayed
(Figure 4B), while Fli1 expression remained the same.
Expression of the PU.1 target gene Csf1r was delayed even
further, indicating that the delay of expression of PU.1 had a
knock-on effect on the expression of downstream genes. Pu.1
contains other enhancer elements at  12 and  10kb, which
depend on PU.1 expression and are activated in macrophages
(Leddin et al, 2011), and which are likely to compensate for
the defect in the URE. This result shows that the FLI1 binding
site is required for the correct developmental timing of
expression of at least two genes essential for myelopoiesis
and macrophage differentiation.
SCL/TAL1 and FLI1 binding proﬁles change during
development
The combinatorial binding of haematopoietic regulators such
as RUNX1, SCL/TAL1 and FLI1 and others speciﬁes cis-
regulatory elements active in haematopoietic cells (Wilson
et al, 2010). However, our analysis indicates that while
haematopoietic genes were bound by SCL/TAL1, FLI1 and
C/EBPb in the HE, these commonly did not bind together
within a 400-bp window. We therefore considered the possi-
bility that they changed position during the speciﬁcation of
haematopoietic cells. To this end we determined the binding
sites of FLI1 and SCL/TAL1 in wild-type c-kitþ/CD41þ/
Tie2  progenitor cells (c-kitþ cells) and obtained 7735 and
8205 peaks, respectively (Figure 5A) and 1371 joint peaks.
The comparison of the overlap of peak regions from the
uninduced HE and c-kitþ cells for the two factors showed
that only a proportion of these regions were shared
(Figure 5C) and the pattern for many individual genes
was different (examples are shown in Figure 5B and
Supplementary Figure 5A, with manual validations depicted
in Supplementary Figure 5B). This was most pronounced for
FLI1 where only a few binding sites were shared between
the two cell types. In addition, the sequence motifs associ-
ated with FLI1 and SCL/TAL1 in c-kitþ cells differed from
those in the HE (Supplementary Figure 5C). Most notable
was a lack of enrichment of AP1-associated consensus
sequences (compare with Figure 3A). Instead, the pattern
resembled that of cis elements active in haematopoietic
cells (Wilson et al, 2010), with GATA and RUNX1 binding
sites featuring prominently. Again, most FLI1 peaks
contained an ETS consensus motif (93%) and more than
half of the SCL peaks featured E-box motifs (58%)
(Supplementary Figure 5D).
The redistribution of FLI1 and SCL/TAL1 towards a haema-
topoietic binding pattern was also indicated when examining
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Figure 5 FLI1 and SCL/TAL1 binding proﬁles in haematopoietic c-kitþ precursor cells. (A) Venn diagram showing the intersection of ChIP-
sequencing data of FLI1 and SCL/TAL1 in c-kitþ/CD41þ/Tie2  (c-kitþ) wild-type progenitor cells prepared on day 4 of blast
differentiation. (B) UCSC genome browser screenshots providing examples of genes where the binding pattern of FLI1 and SCL/TAL1 changes
during differentiation from the uninduced haemogenic endothelium (HE) to c-kitþ progenitors. (C) Venn diagrams showing the overlap of
peaks of SCL/TAL1 (left) and FLI1 (right) between the uninduced HE and wild-type c-kitþ progenitors. (D) Hierarchical clustering of
transcription factor binding sequences in different cell types (data sets from this study are highlighted in blue). Based on similar binding
patterns of the different ChIP-seq data, a correlation matrix was generated and sequence similarities are displayed after hierarchical clustering
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while the peak overlap was relatively low (Figure 5A), around
50% of genes were bound by both factors (Supplementary
Figure 5E, top panel). This was also observed when compar-
ing genes bound by FLI1 and SCL/TAL1, respectively, in the
HE and c-kitþ cells (Supplementary Figure 5E, middle and
bottom panels). GSEA of genes bound by FLI1, SCL/TAL1 and
both factors showed that the genes bound by both factors
had the highest enrichment score for HSC-speciﬁc genes
(Supplementary Figure 5F; Supplementary Table 3). This
suggests that much of the redistribution of factors during
differentiation occurs within one gene locus or in its vicinity.
To substantiate this ﬁnding, we clustered binding sites
according to their sequence similarity and compared them
to a compendium of other, previously published ChIP-
sequencing data sets (Figure 5D). This type of analysis has
demonstrated that binding sites for tissue-speciﬁc transcrip-
tion factors often cluster according to the cell types in which
the factor was analysed, in contrast to CTCF whose binding
sites in different cell types are invariant (Hannah et al, 2011).
Our analysis showed that DNA sequences within peaks
bound by SCL/TAL1 in the HE and in c-kitþ cells relate to
those obtained from ChIP data from the haematopoietic
precursor cell line HPC7 (Wilson et al, 2010), although
there were still sequence similarities with FLI1 bound peaks
in the uninduced HE, as indicated by a signal in the heat
map (see marked grid locations). In contrast, FLI1 bound
sequences in the uninduced HE clustered with those bound
by C/EBPb whereas in the c-kitþ cells they clustered with
SCL/TAL1 (Figure 5D). C/EBPb sites in the uninduced HE
clustered with C/EBPb and C/EBPa sites in macrophages,
suggesting that the macrophage-type C/EBPb occupancy
pattern is established early in development.
Taken together, our results demonstrate that the differen-
tiation from HE into haematopoietic precursor cells is asso-
ciated with a redistribution of SCL/TAL1 and FLI1 to new
binding sites.
RUNX1 binds to genes that are previously bound by
SCL/TAL1, FLI1 and C/EBPb
We next addressed the question of what caused this shift in
binding site patterns. RUNX1 is absolutely required to drive
the differentiation of the HE into haematopoietic cells and for
the activation of important haematopoietic regulator genes,
such as Pu.1 (Sfpi1) (Chen et al, 2009; Hoogenkamp et al,
2009; Lancrin et al, 2009). We therefore investigated the role
of RUNX1 in this shift using the iRUNX1 system. To this end,
we induced RUNX1 expression in the HE by overnight
treatment with low levels of doxycycline as described
(Hoogenkamp et al, 2009) and measured global RUNX1
binding sites (Figure 6A; Supplementary Figure 6A). To test
the effect of RUNX1 induction on active chromatin forma-
tion, we also measured H3K9Ac. Uninduced cells served as
control. We obtained 15669 RUNX1 peaks (Supplementary
Table 1, examples are shown in Figure 6D). In the heat map,
RUNX1 binding sites clustered with those of FLI1 and C/EBPb
sites in the uninduced HE (Figure 5D).
Again, de novo RUNX1 binding sites in the HE did not
always overlap with the binding sites for SCL/TAL1, FLI1 and
C/EBPb (Supplementary Figure 6B, with manual validations
for different genes shown in Supplementary Figure 6C).
Pu.1 (Sfpi1) is one of only a few genes where all factors
bind together to a single cis-regulatory element, the 30 URE
(Figure 6D; Supplementary Figure 6D). However, the gene set
bound by RUNX1 was a subset of that bound by SCL/TAL1,
FLI1 and C/EBPb (Figure 6B) and also showed the highest
enrichment factor for HSC-speciﬁc genes (Figure 6C). In all,
61% of all RUNX1 peaks contained a RUNX1 consensus
sequence. The main motifs associated with RUNX1 sites
were ETS binding sites and AP1 consensus sequences
(Supplementary Figure 6E).
We next examined the pattern of RUNX1 induced genes
using expression microarrays (Supplementary Figure 6F
and G). In all, 1179 genes responded to overnight RUNX1
induction and 64.2% (431/671) of the upregulated and
46.2% (229/508) of the downregulated genes were direct
RUNX1 targets. In all, 16% (188) of these genes were bound
by all four factors (Supplementary Figure 6H). To examine
how important haematopoietic regulator genes respond to
RUNX1 induction, we measured the expression of a number
of these genes in Flk-1þ cells, and in the HE in the presence
and absence of RUNX1 (Supplementary Figure 6I). Despite
containing RUNX1 binding sites (genes marked in black),
genes known to be involved in the regulation of haemato-
poiesis such as Fli1, Tal1, Elf1 and Etv6 did not respond
to RUNX1 induction. The known RUNX1 target genes Pu.1
(Sfpi1) and the regulator of erythropoiesis Nfe2 (Huang
et al, 2008; Wang et al, 2010) were upregulated by RUNX1,
while others such as Erg and Notch1 were downregulated.
The latter result uncovered an interesting potential feedback
loop, as it has been proposed that NOTCH1 is involved
in upregulating Runx1 expression (Nakagawa et al, 2006;
Wang et al, 2010). Cebpa did not respond to RUNX1
induction, and neither did the known RUNX1 target Csf1r.
As shown previously (Hoogenkamp et al, 2009), Csf1r
cannot be bound by RUNX1 at this developmental stage
(Supplementary Figure 6D).
In summary, our data demonstrate that RUNX1 binds to
haematopoietic genes that have previously bound SCL/TAL1,
FLI1 and C/EBPb, but they also show that these factors do not
direct RUNX1 to speciﬁc sequences.
RUNX1 induction activates additional distal
cis-regulatory elements
To test whether RUNX1 preferentially associated with pre-
existing sites of active chromatin or nucleated transcription
factor assembly at new sites, we integrated RUNX1 binding
data with H3K9Ac data. The heat map in Figure 6E shows
that RUNX1 binding sites cluster into two groups. Group I
(Figure 6F, upper panel) consisted mostly of promoter
sequences and was marked by pre-existing H3K9Ac
surrounding the peak, indicating that RUNX1 bound to
pre-existing transcription factor complexes that were ﬂanked
by acetylated histones. The binding of RUNX1 strongly
increased H3K9Ac at these sites and beyond. Group II
(Figure 6F, bottom panel) represents mostly promoter distal
sites of de novo binding that have very low or absent H3K9Ac,
indicating that RUNX1 binding does not commonly require
high levels of active chromatin marks. After RUNX1 binding,
H3K9Ac was strongly increased at these sites and the pattern
indicated the formation of a new factor complex that was
ﬂanked by acetylated histones.
Taken together, our data show that (i) the binding of
RUNX1 does not require pre-existing histone H3K9 acetyla-
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and (ii) the vast majority of de novo RUNX1 binding sites
consist of intergenic and intragenic sites that are likely to
be enhancers.
RUNX1 association leads to a rapid redistribution of
SCL/TAL1 and FLI1 binding
After establishing the RUNX1 binding pattern in the HE, we
tested the hypothesis that the induction of RUNX1 initiated
the shift in the binding pattern of SCL/TAL1 and FLI1 during
the development of haematopoietic precursor cells. We there-
fore measured the genome-wide association of these two
factors in HE cells after overnight induction of RUNX1 and
compared them to the pattern obtained with c-kitþ cells.
We obtained 10395 SCL/TAL1 peaks and 5577 FLI1 peaks in
HE cells after RUNX1 induction (Figure 7A; Supplementary
Table 1). Examples for speciﬁc genes are depicted in
Figure 7B and Supplementary Figure 7A and demonstrate
a striking complexity of alterations of binding patterns
mediated by RUNX1 induction whereby the actual formation
of non-adherent precursor cells does not yet take place. Note
also that a subset of peaks overlap with each other in multiple
individual experiments thus emphasizing the speciﬁcity of
our data. For example, the Sox17 locus that encodes a trans-
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adult HSCs (Kim et al, 2007) was strongly downregulated
after RUNX1 binding (Figure 7B; Supplementary Figure 6I).
While in uninduced and induced cells SCL/TAL1 binding
at the promoter was maintained, it increased FLI1 binding
after induction and all peaks were ﬁnally lost in c-kitþ cells.
At another downregulated gene (Erg) encoding a transcrip-
tion factor important for haematopoiesis (Supplementary
Figure 6I), RUNX1 binding at the promoter caused a reduc-
tion in H3K9Ac, SCL/TAL1 binding was shifted and was
lost in c-kitþ cells (Supplementary Figure 7A and B). The
comparison of the overlap between SCL/TAL1 and FLI1
binding sites between non-induced and induced HE cells as
well as c-kitþ cells demonstrated a steady loss of peak
colocalization with differentiation (HE DOX-HEþDOX-
c-kitþ cells) that was most pronounced with FLI1
(Figure 7A). The latter was also conﬁrmed by clustering
analysis (Figure 5D). While the induction of RUNX1 did not
cause a major change in the position of SCL/TAL1 binding
sites in the heat map, it caused FLI1 binding sequences to
now cluster with those of c-kitþ cells. Again, the overlap
between associated genes was higher than that of peaks
(Supplementary Figure 7C). To further conﬁrm the associa-
tion with SCL/TAL1 and FLI1 with different sequences, we
performed an unbiased motif analysis of binding sites for
each factor unique for HE DOX and HEþDOX. These
analyses demonstrate that after RUNX1 induction both factors
now associate with sequences that were highly enriched for
juxtaposed RUNX1 binding sites, but not before (Figure 7C).
Two potential scenarios could explain the redistribution
of SCL/TAL1 and FLI1. One possibility would be that
RUNX1 binding could either displace SCL/TL1 and FLI1
from their binding sites, alternatively it could attract them to
new locations. To distinguish between these alternatives, we
examined the distances between SCL/TAL1 and FLI1 peaks
and the next RUNX1 peak within a 400-bp window at the
genomic coordinates. SCL/TAL1 and FLI1 peaks were sub-
divided into peaks that were gained or lost within
400bp of a RUNX1 peak on RUNX1 induction (Figure 8A,
Supplementary Figure 8A). In both cases, the number of
gained peaks within 400bp of a new RUNX1 peak was
signiﬁcantly greater than expected by chance and many
peaks were in close proximity (Figure 8B), providing evidence
for RUNX1 attracting SCL/TAL1 and FLI1 to nearby sites. The
number of peaks lost after RUNX1 induction was smaller than
that of gained peaks. In the case of SCL/TAL1, the occurrence
of such peaks was no more than would be expected by
chance. However, in the case of FLI1, there was statistical
evidence that RUNX1 may displace it from its binding sites
(Figure 8B), suggesting that in different contexts RUNX1
binding may either displace FLI1 or attract it. Unbiased
motif analysis of these sequences showed the presence of
RUNX1 motifs in the majority of each peak population (up to
75%), demonstrating the speciﬁcity of our analysis
(Figure 8C). Moreover, 72% of new FLI1 sites also contained
an ETS motif whereas only 37% of new SCL/TAL1 sites
contained an E-Box motif, similar to the pattern described in
a haematopoietic precursor cell line (Wilson et al, 2010).
To further substantiate the ﬁnding that RUNX1 was directly
responsible for the shift in transcription factor binding, we
took advantage of the full temporal control afforded by the
inducible system, and examined whether withdrawal of
RUNX1 following an overnight pulse of induction inﬂuenced
the binding of SCL/TAL1 and FLI1 as well. We therefore
measured binding of RUNX1, FLI-1 and SCL/TAL1 before and
after RUNX1 withdrawal and at binding sites known to
change binding patterns dependent on RUNX1 by manual
ChIP to be able to perform accurate quantiﬁcation (Figure 8E;
Supplementary Figure 8B). We also measured expression and
compared upregulated and downregulated genes by real-time
PCR. At most downregulated genes (Erg, Vav2, Evi1, Notch1,
Ets1), the withdrawal of RUNX1 also altered the binding of
the other factors and expression went back up. This was
independent of the presence of a nearby RUNX1 binding site
(genes with a RUNX1 binding site at the relevant amplicons
are indicated by a red asterisk). At another downregulated
gene, Sox17, the pattern was different, as this gene contained
a stable RUNX1 complex that did not disappear within 24h of
withdrawal. Upregulated RUNX1 target genes showed a simi-
lar complex picture. While at Nfe2, Itga2b (CD41), AI467606
and Gﬁ1 the binding of SCL/TAL1 and/or FLI1 diminished
following RUNX1 withdrawal, this was not true for Pu.1.T h e s e
experiments therefore show a direct requirement for the pre-
sence of RUNX1 for the observed reorganization of SCL/TAL1
and FLI1 binding patterns, and also indicates preferential
retention of RUNX1 protein at a subset of target regions
following the withdrawal of doxycycline induction, reminis-
cent of recently described CTCF binding dynamics following
shRNA mediated knockdown (Schmidt et al,2 0 1 2 ) .
RUNX1 is required for the interaction between trans-
cription factor complexes at speciﬁc genes (Collins et al,
2011; Levantini et al, 2011). Our data suggest that RUNX1
may directly interact with SCL/TAL1 and FLI1 to redirect
their genomic location. To show that RUNX1 forms
complexes with these factors in the HE, we performed
co-immunoprecipitation experiments using nuclear extracts
from induced HE cells (Supplementary Figure 8C) and
showed that this was indeed the case.
Figure 8 SCL/TAL1 and FLI1 move towards RUNX1 peaks after induction. (A) Total number and the percentage of peaks that disappear or
emerge upon RUNX1 induction. (B) Frequency of distances between SCL/TAL1 or FLI1 peaks and the corresponding nearest RUNX1 binding
sites for peaks that were lost (left panel) and peaks that were gained (right panel) after DOX induction. Both SCL/TAL1 and FLI1 gained peak
overlaps with RUNX1 peaks were found to be signiﬁcant (indicated by two asterisks), with Z scores of 107.6 and 34.9, respectively. We found
no evidence that RUNX displaced SCL/TAL (Z¼0.54), however, it had a weak propensity to replace FLI-1 near its binding sites (Z¼24.7, one
asterisk). (C) Unbiased motif analysis of SCL/TAL1 and FLI1 bound regions near RUNX1 sites that were either gained or lost after RUNX1
binding, demonstrating the presence of RUNX1 motifs in each analysed peak population. The analysed peak populations are depicted in
Supplementary Figure 8. (D) Experimental strategy for withdrawal experiments. (E) Expression (upper panels) and factor binding (lower
panels) before and after RUNX1 induction and withdrawal. Amplicons containing a RUNX1 binding site are marked by an asterisk. Error bars
indicate the standard deviation between three independent differentiation and ChIP experiments.
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haematopoietic genes are primed by the binding of SCL/
TAL1, FLI1 and C/EBPb in a pattern that is speciﬁc for the
HE, (ii) that priming is required for the correct temporal
regulation of speciﬁc genes involved in the regulation of
myeloid differentiation and (iii) that RUNX1 redirects the
binding pattern of SCL/TAL1 and FLI1 towards that of
haematopoietic cells.
Lost peaks  Gained peaks 
SCL/TAL1
FLI1
Transcription factor Peaks near RUNX1 binding
sites that are lost after induction 
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Haematopoietic genes are primed in the HE
In the absence of RUNX1 many regulator genes such as
Tal1, Fli1, Lmo2 or Cebpb are already expressed and many
haematopoietic genes are bound by C/EBPb, SCL/TAL1 and
FLI1 at this stage. We also show that at the ﬁrst stage of the
HE SCL/TAL1, FLI1 and C/EBPb largely bind to different
sites, but are already associated with the same genomic
neighbourhood. It has been suggested that coordinately
regulated genes occupy similar areas within the nucleus
and that this colocalization is mediated by speciﬁc transcrip-
tion factors (Schoenfelder et al, 2010). This would explain the
presence of RNA-Pol II at distal and intergenic elements and
suggests that such a binding pattern may be part of the
priming mechanism for haematopoietic genes in the HE.
Such genes would already reside in the appropriate trans-
cription factory facilitating low-level expression and would
be poised for rapid activation in haematopoietic cells.
This is also consistent with our gene expression data. It will
be very interesting to examine whether such elements also
give rise to transcripts with speciﬁc functions in develop-
ment as suggested in Kowalczyk et al (2012). As exempliﬁed
by Sox17, the same mechanism may also allow the rapid
inactivation of genes not expressed in haematopoietic cells
by incoming repressors.
We suggest that the coordinated activation/upregulation of
developmentally regulated genes depends on such priming
events. While it is difﬁcult to show this in a genome-wide
fashion, in the case of Pu.1 we can unambiguously demon-
strate that priming prior to gene activation is essential for the
correct temporal regulation of expression. Here, the inactiva-
tion of an early cis-regulatory element by a binding site
mutation does not abolish expression, but only delays it
until late cis elements are activated and compensate for the
reduction of activity of the URE. This activation involves an
auto-regulatory loop depending on high levels of PU.1 expres-
sion (Pimanda et al, 2007; Leddin et al,2 0 1 1 ) ,w h i c hp r o v i d e s
a mechanistic explanation for the delay. Such compensatory
action may ensure that important genes are always expressed
and differentiation is not completely blocked. Studies with
mice in which the RUNX1 binding site at the Pu.1 30URE was
mutated or where the URE was deleted demonstrated that
progenitor cells expressing low levels of PU.1 reside longer in
the self-renewal stage until PU.1 levels rise high enough to
drive differentiation. Such mice are prone to develop
leukaemia (Rosenbauer et al, 2004; Huang et al, 2008).
SCL/TAL1 and FLI1 binding patterns shift in response to
RUNX1 expression
In early myeloid precursor cells, haematopoietic genes are
bound by transcription factors known to be important for the
development of blood cells, including SCL/TAL1, RUNX1,
FLI1 and GATA2 which colocalize on the same cis-regulatory
elements. The motif composition of these elements reﬂects
this notion (Wilson et al, 2010). However, the factor binding
pattern in the HE prior to the expression of RUNX1 is
different. SCL/TAL1 and FLI1 binding sites mostly do not
overlap and a predominant motif occurring at their binding
sites is an AP1 consensus site, while GATA and RUNX motifs
are not enriched. Endothelial cells contain large numbers of
functional binding sites for AP1 (Linnemann et al, 2011),
suggesting that this factor is part of the binding signature
speciﬁc for endothelial cells and our experiments suggest that
this is also true for the HE. In c-kitþ precursor cells, SCL/
TAL1 and FLI1 associate with motifs for haematopoietic
transcription factors such as GATA, RUNX and ETS family
members and in the clustering analysis now cluster together
with sequences binding these factors in haematopoietic cells
(Wilson et al, 2010; Hannah et al, 2011). RUNX1 induction
causes a rapid shift of the transcription factor binding pattern
towards that observed in c-kitþ precursor cells in the
absence of overt precursor formation. Moreover, RUNX1
initiates changes in the epigenome, including the formation
of new transcription factor complexes with a concomitant
increase in histone acetylation at a large number of newly
formed cis elements. A signiﬁcant fraction of these elements
now bind SCL/TAL1 and FLI1 in close proximity to RUNX1.
RUNX1 is required to mediate long-distance interactions
between distant cis-regulatory elements (Collins et al,2 0 1 1 ;
Levantini et al, 2011) and from our analysis it is likely that
this is the main mechanism by which RUNX1 attracts SCL/
TAL1 and FLI1. The fact that we ﬁnd a physical interaction of
RUNX1 with each of these factors in the induced HE supports
this idea. Another mechanism operating later in development
may be the RUNX1-dependent induction of other trans-
cription factors, notably PU.1. Many ETS factors such as
PU.1 and FLI1 share binding sites, as exempliﬁed by the
Pu.1 50 URE (Hoogenkamp et al, 2007), and it is possible that
PU.1 displaces FLI1 at some of them once it is expressed
at high enough levels and/or provides new interaction
platforms for existing factors.
RUNX1 has previously shown to be expendable in haema-
topoietic precursor cells once they have formed from the HE
(Chen et al, 2009). However, our precisely timed withdrawal
studies indicate that immediately after RUNX1 induction
transcription factor complex assembly at many genes is still
ﬂexible, but not at all of them. Our experiments therefore
suggest a dynamic interplay between RUNX1 and other trans-
cription factors that dictates the half-life of transcription
factor complexes and their dependency on RUNX1. How the
different complexes are stabilized, how this translates into
cell differentiation and how RUNX1 levels come into play will
be a fascinating topic for further investigations.
In summary, the experiments described here highlight a
role of RUNX1 in orchestrating the formation of a haemato-
poiesis-speciﬁc transcription factor binding pattern at the
onset of haematopoietic development. Our study provides a
wealth of data for more in depth mechanistic studies on
transcriptional programming by RUNX1 and its downstream
effector genes.
Materials and methods
ES cell culture
ES cells were maintained on primary embryonic ﬁbroblasts in
DMEM (high glucose) (Sigma D5648), 15% FCS, 1mM Sodium
pyruvate, 50 units/ml Penicillin and 50mg/ml Streptomycin
(Pen/Strep), 1mM glutamine, 0.15mM MTG, 25mM Hepes buffer,
10
3U/ml ESGRO
s (Millipore), 1  non-essential amino acids (Sigma).
Prior to differentiation, the ES cells were grown without ﬁbroblast
feeder cells for two passages on gelatinized tissue culture-treated plates.
ES cell differentiation
A single cell suspension of ES cells was transferred into IVD
media (IMDM with 15% FCS, Pen/Strep, 1mM glutamine,
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50mg/ml ascorbic acid) on 15cm low adherence bacteriological
plates (Sterilin) at a concentration of 2.5 10
4/ml. After 3.25 days,
embryoid bodies were collected and dissociated by digestion with
1  trypsin/EDTA. The cell suspension was resuspended in
IMDMþ20% FCS. Flk-1þ (CD309) cells were isolated using a
biotinylated Flk-1 antibody (eBioscience 13-5821) used at 5ml per
10
7 cells for 10min on ice, followed by 2  wash with MACS buffer
(PBSþ5% BSA and 0.5mM EDTA). Cells bound by the antibody
were then isolated using antibiotin beads and MACS LS columns
(Miltenyi Biotec) according to manufacturer’s instructions.
Blast culture and the differentiation of HE and haematopoietic
precursor cells have been described in Lancrin et al (2009) and
Sroczynska et al (2009b). A detailed description of these methods
can be found in Supplementary Materials and Methods.
Chromatin immunoprecipitation
Differentiated ES cells were crosslinked for 10min at room tem-
perature with 1% formaldehyde (Pierce, Rockford, IL, USA) and
quenched with 1/10 volume 2M glycine. Nuclei were essentially
prepared as described previously (Lefevre et al, 2003). For a more
detailed description of the ChIP, see Supplementary Materials and
Methods. Antibodies used for ChIP were C/EBPb Santa Cruz SC-
150, FLI1 Santa Cruz SC-356, PU.1 Santa Cruz SC-352, RUNX1
Abcam ab23980, SCL/TAL1 Santa Cruz SC-12984, RNA-Pol II ab817,
H3K9Ac ab4441, H3 ab1791 and HA Sigma H6908. Precipitated
material was subjected to library preparation and run on an
Illumina genome analyzer. A detailed protocol for manual library
preparation can be found in Supplementary Methods.
mRNA expression analysis
RNA was extracted from cells using TRIzol
s (Invitrogen) according
to manufacturer’s instruction. First-strand cDNA synthesis was
carried out using M-MLV reverse transcriptase (Invitrogen) accord-
ing to manufacturer’s instructions using 1–2mg of RNA. Real-time
PCR was carried out using ABI SYBR
s green master mix with
2ml of diluted cDNA and 0.25mM primer per 10ml reaction on
an ABI 7500 machine. The analysis was carried out at least on
biological triplicates measured in duplicate. See Supplementary
Table 2 for primer sequences. Microarray expression experiments
were performed on whole mouse gene expression microarrays
(60K, Agilent) using three independent biological replicates showing
Pearson correlation coefﬁcients between 0.977 and 1.00.
Co-immunoprecipitation assay
Inducible RUNX1 (iRUNX1) ES cells were differentiated into HE
and induced overnight with 0.3mg/ml doxycyclin. Approximately
1.2 10
7 cells were lysed with buffer P (300mM NaCl, 20mM
HEPES pH 7.5, 0.5mM EDTA, 0.1% Triton X-100, 0.5mM sodium
vanadate, 2mM NaF, 2mM DTT, 0.1mM PMSF, proteinase inhibitor
mix). The extract was diluted 1:1 with buffer P without 300mM
sodium chloride and then incubated with Protein A/G dynabeads
previously coupled with 2mg of the corresponding antibodies or a
non-speciﬁc control antibody overnight. After washing with buffer
P, the immunoprecipitated proteins were eluted by incubation with
non-reducing SDS sample buffer. Inputs and precipitated samples
were analysed by western blot using an HA-speciﬁc antibody.
The antibodies used for immunoprecipitation and detection were
the same as those used for ChIP. Control antibodies were normal
rabbit IgG sc-2027 and normal goat IgG sc-2028.
Generation of homozygous Pu.1 knock-in mutant ES cells
Pu.1 site in Pu.1 URE mutant knock-in (KI) heterozygous ES
cells containing one copy of neo (clone C4853 kindly provided
by Dan Tenen) were plated at 5 10
5 cells per Ø 10cm plate of
mitomycin-C-treated STO feeder cells. Cells were incubated over-
night before changing the ES culture media/LIF to media plus
2.0mg/ml G418. Surviving colonies were picked after 2 weeks,
expanded on new STO feeder cells in the presence of 2mg/ml G418
and frozen stocks made. An aliquot of each clone was grown on
0.1% gelatin-coated tissue culture ﬂasks for DNA extraction in
order to perform PCR genotyping. The primers used for the PU.1
site mut-KI were mA/mP/KI/sense: TGTTTCGAGAACCGAAGGGA
ATGAC and mA/mP/KI/antisense: AGCTGGACCGGAGGATCTGCGG
AAC; PCR products (WT 400 and KI 500bp) were separated on a
1% agarose gel.
Data analysis
A detailed description of data analyses can be found in
Supplementary Materials.
Data accession numbers
All high-throughput data have been deposited at GEO (accession
number GSE40235).
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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